Moderna reports third quarter revenue of $1.0 billion and net loss of $0.2 billion
Reuters
Nov 06
<a href="https://laohu8.com/S/MRNA">Moderna</a> reports third quarter revenue of $1.0 billion and net loss of $0.2 billion
Moderna Inc. reported third quarter 2025 revenue of $1.0 billion, with a GAAP net loss of $0.2 billion and GAAP earnings per share of $(0.51). The company narrowed its projected 2025 revenue range to $1.6-$2.0 billion, reduced expected 2025 GAAP operating expenses to $5.2-$5.4 billion, and increased its expected year-end cash balance to $6.5-$7.0 billion. COVID vaccine sales for the third quarter totaled $971 million, including $781 million in the U.S. and $190 million internationally. The company received FDA approval for its 2025-2026 mNEXSPIKE COVID vaccine for adults aged 65 and older and certain younger individuals with risk factors, with approvals also granted in Canada and filings in other regions. Capital expenditures for 2025 are expected to be approximately $0.3 billion. Moderna also presented Phase 3 data for its seasonal flu vaccine and plans to complete regulatory submissions by January 2026 in several countries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001682852-25-000073), on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.